The abstract focuses on the development of a bispecific antibody, TJ-CD4B, targeting
Claudin 18.2 (CLDN18.2), a protein overexpressed in various
solid tumors, making it a promising target for
cancer immunotherapy. TJ-CD4B is designed to engage the
4-1BB antigen, redirecting and activating T cells to target CLDN18.2 positive tumor cells.
The antibody's binding capability was assessed through protein and cell-based assays, demonstrating a stronger affinity for CLDN18.2 compared to a benchmark monoclonal antibody (IMAB362). TJ-CD4B's functionality was evaluated using a 4-1BB signaling reporter assay and primary human T cell assay, showing activation of 4-1BB signaling dependent on CLDN18.2 expression.
In a humanized 4-1BB mouse model with CLDN18.2 overexpressing
colon cancer cells, TJ-CD4B exhibited robust tumor growth inhibition (TGI) and increased tumor infiltrating lymphocytes without affecting peripheral lymphocytes, suggesting a minimized risk of peripheral toxicity.
The study concludes that TJ-CD4B has shown potent anti-tumor activity specifically in the tumor microenvironment, supporting its further development. The antibody is considered reasonably developable and is expected to enter clinical trials in early 2021.
The research was presented at the Annual Meeting of the American Association for Cancer Research in 2020, highlighting its significance in the field of cancer therapy.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
